Bradley Evans, MD
Cardiovascular Disease · Gresham, ORNPI 1568464261
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,600 of the $5,845 with a category attached, or 95.8%. Endologix LLC accounts for 95.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,759 and has fallen 99.7% since, to $16 in 2025.
Across 13 payments — averaging $449.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$6K
- Philips North America LLC$105
- Abbott$52
- Pfizer$21
- Cardiovascular Systems Inc.$21
- Heartflow, Inc.$20
- plus $27 from 2 others
Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endologix LLC$300
What the payments were for
- Consulting fees$5,60096%
- Food & beverage$2454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 3 | $5,600 |
| Philips North America LLC | 3 | $105 |
| Abbott | 2 | $52 |
| Pfizer | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $21 |
| Heartflow, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ovation$5,600
How this compares
$5,845 in reported general payments places this provider in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $182,063 |
| FarxigaDapagliflozin Propanediol | 80 | $88,728 |
| JardianceEmpagliflozin | 49 | $54,078 |
| EntrestoSacubitril/Valsartan | 32 | $44,132 |
| XareltoRivaroxaban | 14 | $19,353 |
| Praluent PenAlirocumab | 15 | $13,303 |
| Rosuvastatin Calcium | 95 | $1,917 |
| Atorvastatin Calcium | 155 | $1,591 |
| Metoprolol Succinate | 80 | $1,264 |
| Losartan Potassium | 119 | $1,047 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $1,014 |
| ClopidogrelClopidogrel Bisulfate | 49 | $601 |
| Atenolol | 88 | $569 |
| Amlodipine Besylate | 53 | $378 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 37 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $182,063147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Gresham
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.